Chong Kun Dang Pharmaceutical Corp.
185750.KS
Get informed when a big investor buys or sells
+ FollowMarket Cap$868.3B
Close$
$57641.70
11.6% downside
Current Fair Value
11.6% downsideOvervalued by 11.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $868.30 Billion |
|---|---|
| Enterprise Value | $1.12 Trillion |
| Dividend Yield | $500.00 (0.76%) |
| Earnings per Share | $5882.09 |
| Beta | -0.43 |
| Outstanding Shares | 13,803,000 |
Return
| Return on Equity | 7.83% |
|---|---|
| Return on Assets | 4.26% |
| Return on Invested Capital | 5.84% |
Valuation & Multiples
| P/E Ratio | 10.93 |
|---|---|
| PEG | 224.59 |
| Price to Sales | 0.5 |
| Price to Book Ratio | 0.88 |
| Enterprise Value to Revenue | 0.63 |
| Enterprise Value to EBIT | 14.32 |
| Enterprise Value to Net Income | 14 |
| Total Debt to Enterprise | 0.4 |
| Debt to Equity | 0.44 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 31, 2026
EPS Estimate
$2544.00
Average shareholder expectationRevenue Estimate
$474.06 B
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$1653.00
Average shareholder expectationRevenue Estimate
$478.57 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Chong Kun Dang Pharmaceutical Corp.
2,304 employees
CEO: Young-Ju Kim Chong Kun Dang Pharmaceutical Corp. engages in the manufacture, distribution, research, and development of pharmaceuticals. Its products include medicine for antidiabetics, antiviruses, beta-blockers, anti-hyperlipidemia, and others. The...